Join to view full profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Fax+1 650-723-7299
Dr. Day is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Residency, Neurology, 1983 - 1986
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Internship, Internal Medicine, 1982 - 1983
University of Minnesota Medical SchoolClass of 1977
Certifications & Licensure
CA State Medical License 2011 - 2027
MN State Medical License 1992 - 2022
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
Clinical Trials
- Natural History Evaluation of Charcot Marie Tooth Disease (CMT) Types CMT1B, CMT2A, CMT4A, CMT4C, and Others Start of enrollment: 2010 Apr 01
- A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy Start of enrollment: 2014 Aug 19
- Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Start of enrollment: 2015 Jun 30
Publications & Presentations
PubMed
- Cardiac Safety Outcomes in Delandistrogene Moxeparvovec Clinical Trials for Duchenne Muscular Dystrophy with Up to 5 Years of Follow-up.Aravindhan Veerapandiyan, John Bourke, Jonathan H Soslow, John W Day, Craig M McDonald
Cardiology and Therapy. 2026-09-01 - 1 citationsEfficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.Maria Mazurkiewicz-Bełdzińska, Laurent Servais, Giovanni Baranello, Odile Boespflug-Tanguy, John W Day
The Lancet. Child & Adolescent Health. 2026-09-01 - Identification of prognostic biomarkers in a large cohort of patients with LGMD R2.Carla F Bolano-Diaz, Jose Verdu-Diaz, Dan Hao, Meredith K James, Laura Rufibach
Journal of Neurology. 2026-05-26
Journal Articles
- Telomere Shortening Is a Hallmark of Genetic CardiomyopathiesChristine E Seidman, John T Hinson, Gerhard Weber, Euan Ashley, John W Day, Joseph C Wu, Proceedings of the National Academy of Sciences
Press Mentions
Itvisma Wins FDA Approval as Novartis’ Second SMA Gene TherapyNovember 25th, 2025- Smartphones Can Monitor Patients with Neuromuscular DiseasesNovember 3rd, 2025
- Smartphones Match Traditional Methods in Monitoring Patients with Muscular DystrophyNovember 2nd, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
